YALDOO LAITH L 4

What Happened Laith L. Yaldoo, reported as a 10% owner of Zivo Bioscience, purchased 2,434 shares on February 10, 2026. The transaction is reported as a purchase (code P) at $10.27 per share, for a total acquisition cost of $24,997. This was an outright share purchase (open-market or private purchase as reported), which is a direct buy rather than a sale or option exercise.

Key Details

• Transaction date: 2026-02-10; Filing date: 2026-02-12 (Form 4 accession 0001654954-26-001157). Filing appears timely (within the typical two-business-day window).
• Shares acquired: 2,434 at $10.27 per share; Total value: $24,997.
• Transaction code: P (purchase — open market or private purchase).
• Shares owned after transaction: Not specified in the provided filing details.
• No footnotes, 10b5-1 plan designation, tax withholding, or derivative activity disclosed in the summary information provided.

Context

• Purchases by large shareholders (10% owners) are informative because they show direct, personal investment, but they do not necessarily reflect management-level trading intentions. This is a straightforward buy, not an option exercise, gift, or tax-related transfer.
• Retail investors often treat purchases by insiders or large owners as a more meaningful signal than routine sales, but filings alone don’t explain motive (e.g., long-term confidence, portfolio rebalancing, or other reasons).